Mirum Pharmaceuticals (NASDAQ:MIRM) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.32) by 6.25 percent. This is a 44.44 percent increase over losses of $(0.54) per share from the same period last year. The company reported quarterly sales of $111.60 million which beat the analyst consensus estimate of $98.40 million by 13.41 percent. This is a 61.22 percent increase over sales of $69.22 million the same period last year.